Professor David Roblin, FRCP FMedSci

David is a distinguished scientist, physician, entrepreneur in pharma, biotech and academia with extensive experience in C-suite and Board roles. He is currently CEO of Relation Therapeutics and is a non-executive director of Sosei.

He has operated from bedside to bench and industry to academia. After 5 years of medical practice in university hospitals, for over 20 years he held senior positions in Bayer and at Pfizer finally as SVP and Head of European R&D before entering biotech; leading people (up to 5,000), products, therapy areas and global disciplines. His experience crosses therapy areas from research and development to commercial phases. At Pfizer and Bayer he was instrumental in the successful development of many important medicines for infectious diseases including azithromycin, ciprofloxacin and moxifloxacin.

He served as the Chief Operating Officer and first Director of Scientific Translation at the Francis Crick Institute in London (2014 – 2017) where he continues as the Chair of Scientific Translation. The Crick translational efforts have raised around £700M of external investments.

He has raised substantial capital on the public markets (US/UK/Japan), from venture and private investor as well as a range of corporate transactions, such as collaborations, licensing, and non-dilutive grants.

David has a degree in biochemistry from University of London and qualified in Medicine from St George’s Hospital, London. He is a Fellow of the Royal College of Physicians, Fellow of the Faculty of Pharmaceutical Medicine and a Fellow of the Academy of Medical Sciences and a Global Medicine Development Fellow of IFPMA. He is an honorary Professor of Medicine at Swansea University and Professor of Translational Medicine at St George’s.